Drug Trial Radar · NCT06213506
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jan 15, 2024
Primary completion
Aug 6, 2026
Study completion Aug 6, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then in children (24-59 months of age) and finally in infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.
Conditions
- Salmonella Infections
Interventions
iNTS-GMMA Dose CBiological
-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 and at Day 232 to infants in the Infants\_6W\_Dose C group.
iNTS-GMMA Dose BBiological
-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 and Day at 232 to infants in the Infants\_6W\_Dose B group.
iNTS-GMMA Dose ABiological
3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 and Day at 232 to infants in the Infants\_6W\_Dose A group.
MenACWYBiological
-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 and at Day 232 to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B and Infants\_6W\_Control C groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
DTPa-HBV-IPV+HibCombination product
1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.
PlaceboDrug
1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.
Measles and Rubella vaccineBiological
Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups.
Yellow Fever vaccineBiological
Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adult participants 18-50 years of age with solicited administration site eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of adult participants 18-50 years of age with solicited administration site eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of adult participants 18-50 years of age with solicited systemic eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of adult participants 18-50 years of age with solicited systemic eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of adult participants 18-50 years of age with unsolicited adverse events (AEs)Time frame: During 28 days after the first study intervention administration occurring at Day 1
- Number of adult participants 18-50 years of age with unsolicited adverse events (AEs)Time frame: During 28 days after the second study intervention administration occurring at Day 57
- Number of adult participants 18-50 years of age with serious adverse events (SAEs)Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)
- Number of adult participants 18-50 years of age with adverse events (AEs) leading to withdrawal from the study or discontinuation of study interventionTime frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)
- Number of adult participants 18-50 years of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 8 (7 days after the first study intervention administration)
- Number of adult participants 18-50 years of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 64 (7 days after the second study intervention administration)
- Number of child participants 24-59 months of age with solicited administration site eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of child participants 24-59 months of age with solicited administration site eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of child participants 24-59 months of age with solicited systemic eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of child participants 24-59 months of age with solicited systemic eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of child participants 24-59 months of age with unsolicited AEsTime frame: During 28 days after the first study intervention administration occurring at Day 1
- Number of child participants 24-59 months of age with unsolicited AEsTime frame: During 28 days after the second study intervention administration occurring at Day 57
- Number of child participants 24-59 months of age with serious adverse events (SAEs)Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)
- Number of child participants 24-59 months of age with AEs leading to withdrawal from the study or discontinuation of study interventionTime frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)
- Number of child participants 24-59 months of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 8 (7 days after the first study intervention administration)
- Number of child participants 24-59 months of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 64 (7 days after the second study intervention administration)
- Number of infant participants 9 months of age with solicited administration site eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of infant participants 9 months of age with solicited administration site eventsTime frame: During 7 days after the second study intervention administration occurring at Day 85
- Number of infant participants 9 months of age with solicited administration site eventsTime frame: During 7 days after the third study intervention administration occurring at Day 169
- Number of infant participants 9 months of age with solicited systemic eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of infant participants 9 months of age with solicited systemic eventsTime frame: During 7 days after the second study intervention administration occurring at Day 85
- Number of infant participants 9 months of age with solicited systemic eventsTime frame: During 7 days after the third study intervention administration occurring at Day 169
- Number of infant participants 9 months of age with unsolicited adverse events (AEs)Time frame: During 28 days after the first study intervention administration occurring at Day 1
- Number of infant participants 9 months of age with unsolicited adverse events (AEs)Time frame: During 28 days after the second study intervention administration occurring at Day 85
- Number of infant participants 9 months of age with unsolicited adverse events (AEs)Time frame: During 28 days after the third study intervention administration occurring at Day 169
- Number of infant participants 9 months of age with serious adverse events (SAEs)Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 337)
- Number of infant participants 9 months of age with adverse events (AEs) leading to withdrawal from the study or discontinuation of study interventionTime frame: From first study intervention administration (Day 1) up to the end of study participation (Day 337)
- Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 8 (7 days after the first study intervention administration)
- Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 92 (7 days after the second study intervention administration)
- Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test resultsTime frame: At Day 176 (7 days after the third study intervention administration)
- Number of infant participants 6 weeks of age with solicited administration site eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of infant participants 6 weeks of age with solicited administration site eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of infant participants 6 weeks of age with solicited systemic eventsTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of infant participants 6 weeks of age with solicited systemic eventsTime frame: During 7 days after the second study intervention administration occurring at Day 57
- Number of infant participants 6 weeks of age with unsolicited adverse events (AEs)Time frame: During 28 days after the first study intervention administration occurring at Day 1
- Number of infant participants 6 weeks of age with unsolicited adverse events (AEs)Time frame: During 28 days after the second study intervention administration occurring at Day 57
- Number of infant participants 6 weeks of age with SAEsTime frame: From first study intervention administration (Day 1) up to 28 days after second study intervention (Day 85)
- Number of infant participants 6 weeks of age with adverse events (AEs) leading to MR-VAC administration withdrawal from the study or discontinuation of study interventionTime frame: From first study intervention administration (Day 1) up to 28 days after second study intervention (Day 85)
- Number of infant participants 6 weeks of age with deviations from reference ranges or baseline values for hematological, renal, and hepatic panel test resultsTime frame: At Day 8 (7 days after the first study intervention administration)
- Number of infant participants 6 weeks of age with deviations from reference ranges or baseline values for hematological, renal, and hepatic panel test results at Day 64Time frame: At Day 64 (7 days after the second study intervention administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Kumasi, Ghana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.